glp 1 cardiac protection Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology GLP-1 Receptor Agonists in Heart

FDA approved orforglipron in 50 days

Tirz epatide has undergone extensivePhase 3 clinical evaluation in large, controlled trials

Summary A targeted and individualized nutrition and physical activity regimen should be instituted for each patient with a focus on optimizing protein intake and performing frequent resistance training in order to minimize loss of muscle mass while promoting the loss of fat mass

No one-size-fits-all plans

Yeast infections are a reported side effect in some people taking semaglutide and other GLP-1 receptor agonists

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month